Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TargetFlame: add-on celecoxib in schizophrenia spectrum disorders with inflammatory profile
2021-002572-39Phase 3Completed
- Sponsor
- Bezirkskliniken Schwaben
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) comparing Celecoxib add-on with Placebo add-on (2 arms). Primary endpoint: Primary efficacy endpoint. Started Dec 2021; status: completed.
02
Drugs
celecoxib
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)
Beyond the preview
Go deeper on 2021-002572-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002572-39.